Whole-genome analysis informs breast cancer response to aromatase inhibitionMatthew J. Ellis, Mark A. Watson, John A. Olson et al.|Nature|2012Cited by 1k
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)Matthew J. Ellis, Kelly K. Hunt, Vera J. Suman et al.|Journal of Clinical Oncology|2017Cited by 411
Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy.Thomas E. Witzig, Kenneth D. Bauer, Blaise Bossy et al.|PubMed|2002Cited by 156
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast CancerJonathan T. Lei, Matthew J. Ellis, Jieya Shao et al.|Cell Reports|2018Cited by 110
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast CancerX. Cynthia, Matthew J. Ellis, Vera J. Suman et al.|Clinical Cancer Research|2017Cited by 74